121 related articles for article (PubMed ID: 23704049)
21. The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).
Sekeres MA; Swern AS; Giagounidis A; List AF; Selleslag D; Mittelman M; Schlegelberger B; Göhring G; Li JS; Sugrue MM; Fenaux P
Blood Cancer J; 2018 Sep; 8(10):90. PubMed ID: 30291223
[No Abstract] [Full Text] [Related]
22. Adjusted dose lenalidomide is safe and effective in patients with deletion (5q) myelodysplastic syndrome and severe renal impairment.
Knop S; Einsele H; Bargou R; Cosgrove D; List A
Leuk Lymphoma; 2008 Feb; 49(2):346-9. PubMed ID: 18231924
[No Abstract] [Full Text] [Related]
23. Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q.
Panagiota V; Meggendorfer M; Kubasch AS; Gabdoulline R; Krönke J; Mies A; Shahswar R; Kandziora C; Klement P; Schiller J; Göhring G; Haferlach C; Ganster C; Shirneshan K; Gutermuth A; Thiede C; Germing U; Schroeder T; Kobbe G; Klesse S; Koenecke C; Schlegelberger B; Kröger N; Haase D; Döhner K; Sperr WR; Valent P; Ganser A; Thol F; Haferlach T; Platzbecker U; Heuser M
Am J Hematol; 2021 Jun; 96(6):E207-E210. PubMed ID: 33725366
[No Abstract] [Full Text] [Related]
24. A paediatric myelodysplastic syndrome with 5q deletion associated with Fanconi anaemia.
Kornreich L; Soulier J; Grange B; Girard S; Ouchée-Chardin M; Ceraulo A
Pediatr Blood Cancer; 2020 Jul; 67(7):e28369. PubMed ID: 32379395
[No Abstract] [Full Text] [Related]
25. Revealing the pathogenesis of the 5q- syndrome.
Valent P
Eur J Clin Invest; 2008 Aug; 38(8):539-40. PubMed ID: 18717823
[No Abstract] [Full Text] [Related]
26. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
[No Abstract] [Full Text] [Related]
27. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
Eclache V; Da Rocha A; Le Roux G; Fenaux P
Haematologica; 2008 Feb; 93(2):315-6. PubMed ID: 18245660
[TBL] [Abstract][Full Text] [Related]
28. [Myelodysplastic syndrome with chromosome 5q deletion and philadelphia chromosome: case report and literatures review].
Zhang YQ; Liu RT; Pan JQ; Xu P; Li XY; Yu LQ; Gao HY; Jiang YF
Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):940-942. PubMed ID: 33333699
[No Abstract] [Full Text] [Related]
29. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow morphology in myelodysplastic syndrome associated with isolated del(5q).
Naresh KN; Reid A
Am J Hematol; 2010 Aug; 85(8):609-10. PubMed ID: 20658591
[No Abstract] [Full Text] [Related]
31. Deletion of 5q31 is observed in megakaryocytic cells in patients with myelodysplastic syndromes and a del(5q), including the 5q- syndrome.
Godon C; Talmant P; Garand R; Accart F; Bataille R; Avet-Loiseau H
Genes Chromosomes Cancer; 2000 Dec; 29(4):350-2. PubMed ID: 11066080
[TBL] [Abstract][Full Text] [Related]
32. Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.
Mährle T; Akyüz N; Fuchs P; Bonzanni N; Simnica D; Germing U; Asemissen AM; Jann JC; Nolte F; Hofmann WK; Nowak D; Binder M
Haematologica; 2019 Jul; 104(7):1355-1364. PubMed ID: 30655375
[TBL] [Abstract][Full Text] [Related]
33. Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
Oka S; Ono K; Nohgawa M
Leuk Lymphoma; 2017 Oct; 58(10):2511-2513. PubMed ID: 28278708
[No Abstract] [Full Text] [Related]
34. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).
Fidler C; Watkins F; Bowen DT; Littlewood TJ; Wainscoat JS; Boultwood J
Haematologica; 2004 Jul; 89(7):865-6. PubMed ID: 15257941
[TBL] [Abstract][Full Text] [Related]
35. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
[TBL] [Abstract][Full Text] [Related]
36. NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype.
Ammatuna E; Panetta P; Agirre X; Ottone T; Lavorgna S; Calasanz MJ; Lo-Coco F
Haematologica; 2011 May; 96(5):784-5. PubMed ID: 21393327
[No Abstract] [Full Text] [Related]
37. Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS).
Mossner M; Jann JC; Nowak D; Platzbecker U; Giagounidis A; Götze K; Letsch A; Haase D; Shirneshan K; Braulke F; Schlenk RF; Haferlach T; Schafhausen P; Bug G; Lübbert M; Ganser A; Büsche G; Schuler E; Nowak V; Pressler J; Obländer J; Fey S; Müller N; Lauinger-Lörsch E; Metzgeroth G; Weiß C; Hofmann WK; Germing U; Nolte F
Leukemia; 2016 Sep; 30(9):1956-9. PubMed ID: 27133825
[No Abstract] [Full Text] [Related]
38. Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis.
Cazzola M
Haematologica; 2008 Jul; 93(7):967-72. PubMed ID: 18591621
[No Abstract] [Full Text] [Related]
39. The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.
Kuendgen A
Leuk Res; 2014 Mar; 38(3):287-8. PubMed ID: 24433864
[No Abstract] [Full Text] [Related]
40. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
